Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma
Status:
Withdrawn
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Double-blind study will compare the efficacy and assess safety of selinexor plus carfilzomib
(Kyprolis®) plus low-dose dexamethasone versus placebo plus carfilzomib plus low-dose
dexamethasone in patients with relapsed/refractory multiple myeloma.